Can-Fite Biopharma Ltd ADR (CANF): Next-Year EPS Estimate 75.00%
As of 2026-06-04, Can-Fite Biopharma Ltd ADR (CANF) has a next-year EPS growth estimate of 75.00%.
On 2026-05-24, analyst consensus for CANF's next-year EPS growth shifted from 67.38% to 75.00% — a positive change of 7.62 percentage points. The revised estimate has been sustained across 10 subsequent trading sessions. Current-year growth is projected at 82.58%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 75.00%
- EPS growth this year
- 82.58%
- EPS next quarter (est)
- -$0.51
- Last price
- $3.16
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 75.00% | 82.58% | -$0.51 | $3.16 |
| 2026-06-03 | 75.00% | 82.58% | -$0.51 | $3.11 |
| 2026-06-02 | 75.00% | 82.58% | -$0.51 | $3.11 |
| 2026-06-01 | 75.00% | 82.58% | -$0.51 | $3.24 |
| 2026-05-31 | 75.00% | 82.58% | -$0.51 | $3.35 |
| 2026-05-28 | 75.00% | 82.58% | -$0.51 | $3.36 |
| 2026-05-27 | 75.00% | 82.58% | -$0.51 | $3.35 |
| 2026-05-26 | 75.00% | 82.58% | -$0.51 | $3.44 |
| 2026-05-25 | 75.00% | 82.58% | -$0.51 | $3.40 |
| 2026-05-24 | 75.00% | 82.58% | -$0.51 | $3.40 |
| 2026-05-21 | 67.38% | 84.34% | -$1.43 | $3.44 |
| 2026-05-20 | 67.38% | 84.34% | -$1.43 | $3.46 |
| 2026-05-19 | 67.38% | 84.34% | -$1.43 | $3.25 |
| 2026-05-18 | 67.38% | 84.34% | -$1.43 | $3.26 |
| 2026-05-17 | 67.38% | 84.34% | -$1.43 | $3.36 |
| 2026-05-14 | 67.38% | 84.34% | -$1.43 | $3.49 |
| 2026-05-13 | 67.38% | 84.34% | -$1.43 | $3.60 |
| 2026-05-12 | 67.38% | 84.34% | -$1.43 | $3.39 |
| 2026-05-11 | 57.83% | 86.10% | -$1.43 | $3.36 |
| 2026-05-10 | 57.83% | 86.10% | -$1.43 | $3.51 |
| 2026-05-07 | 57.83% | 86.10% | -$1.43 | $3.54 |
| 2026-05-06 | 57.83% | 86.10% | -$1.43 | $3.35 |
| 2026-05-05 | 57.83% | 86.10% | -$1.43 | $3.50 |
| 2026-05-04 | 57.83% | 86.10% | -$1.43 | $3.32 |
| 2026-05-03 | 57.83% | 86.10% | -$1.43 | $2.93 |
| 2026-04-30 | 57.83% | 86.10% | -$1.43 | $3.19 |
| 2026-04-29 | 57.83% | 86.10% | -$1.43 | $2.99 |
| 2026-04-28 | 57.83% | 86.10% | -$1.43 | $2.91 |
| 2026-04-27 | 57.83% | 86.10% | -$1.43 | $2.92 |
| 2026-04-26 | 57.83% | 86.10% | -$1.43 | $2.91 |
Recent News
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Can-Fite Biopharma Ltd ADR's next-year EPS growth estimate?▾
As of 2026-06-04, Can-Fite Biopharma Ltd ADR (CANF) has a next-year EPS growth estimate of 75.00%, based on analyst consensus.
When was the latest EPS estimate revision for CANF?▾
The most recent revision occurred on 2026-05-24, when analysts adjusted the next-year EPS growth estimate from 67.38% to 75.00%.
What sector and industry does Can-Fite Biopharma Ltd ADR belong to?▾
Can-Fite Biopharma Ltd ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. CANF appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Can-Fite Biopharma Ltd ADR (CANF) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports